| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PLA2G12A |
| Uniprot No | Q9BZM1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-185aa |
| 氨基酸序列 | QEQAQTTDWRATLKTIRNGVHKIDTYLNAALDLLGGEDGLCQYKCSDGSKPFPRYGYKPSPPNGCGSPLFGVHLNIGIPSLTKCCNQHDRCYETCGKSKNDCDEEFQYCLSKICRDVQKTLGLTQHVQACETTVELLFDSVIHLGCKPYLDSQRAACRCHYEE |
| 预测分子量 | 20.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PLA2G12A重组蛋白的3篇代表性参考文献示例(内容为模拟，仅供参考)：
1. **文献名称**：*"Recombinant PLA2G12A exhibits phospholipase activity and modulates lipid droplet formation in hepatocytes"*
**作者**：Zhang Y, et al.
**摘要**：本研究成功在大肠杆菌中表达并纯化了具有活性的PLA2G12A重组蛋白，证实其可水解磷脂酰胆碱生成溶血磷脂和脂肪酸。实验发现该蛋白通过调节肝细胞脂滴形成影响脂代谢，为探究其在代谢疾病中的作用提供了工具。
2. **文献名称**：*"Structural characterization of human PLA2G12A reveals unique features among secretory phospholipases A2"*
**作者**：Lee S, Smith J, et al.
**摘要**：通过X射线晶体学解析了PLA2G12A重组蛋白的三维结构，发现其钙离子结合位点和催化口袋的独特构象，揭示了与其他分泌型PLA2家族成员的功能差异，为靶向药物设计提供了结构基础。
3. **文献名称**：*"PLA2G12A recombinant protein inhibits hepatitis C virus replication by altering viral membrane composition"*
**作者**：Brown AL, et al.
**摘要**：研究发现，外源添加PLA2G12A重组蛋白可通过改变宿主细胞膜脂质组成，干扰HCV病毒颗粒的组装和释放，提示其在抗病毒治疗中的潜在应用价值。
注：以上文献为示例性质，实际研究中请通过PubMed或Web of Science等平台检索最新发表的具体论文。
**Background of PLA2G12A Recombinant Protein**
PLA2G12A (Phospholipase A2 Group XIIA) is a secreted enzyme belonging to the phospholipase A2 (PLA2) superfamily, which catalyzes the hydrolysis of phospholipids to release fatty acids and lysophospholipids. Unlike other PLA2 members, PLA2G12A exhibits unique structural and functional characteristics. It is encoded by the *PLA2G12A* gene and contains a conserved PLA2 domain with 12 cysteine residues forming six disulfide bonds, critical for its stability and enzymatic activity.
PLA2G12A is implicated in lipid metabolism, inflammation, and lipoprotein remodeling. Studies suggest its role in regulating plasma lipid levels, particularly high-density lipoprotein (HDL) metabolism, and its potential association with metabolic disorders such as atherosclerosis and non-alcoholic fatty liver disease (NAFLD). However, its precise mechanisms remain under investigation, partly due to challenges in characterizing its enzymatic activity and substrate specificity.
Recombinant PLA2G12A protein is produced using heterologous expression systems (e.g., mammalian cells or *E. coli*) to enable functional and structural studies. This engineered protein retains the enzymatic properties of native PLA2G12A, allowing researchers to explore its interactions with lipoproteins, cell membranes, and inhibitors. Its recombinant form is essential for *in vitro* assays, antibody development, and drug discovery targeting PLA2G12A-associated pathways.
Recent research highlights PLA2G12A's dual role as both a phospholipase and a signaling molecule, influencing inflammatory responses and metabolic homeostasis. Its recombinant variant serves as a valuable tool to dissect its contribution to diseases like diabetes, cardiovascular disorders, and cancer, while also exploring therapeutic strategies to modulate its activity. Further studies are needed to clarify its physiological and pathological roles, positioning PLA2G12A recombinant protein as a critical resource in biomedical research.
×
